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a b s t r a c t 
Multiple sclerosis (MS) is an inﬂammatory and neurodegenerative disease of the central nervous system. 
While current medication reduces relapses and inﬂammatory activity, it has only a modest effect on long- 
term disability and gray matter atrophy. Here, we have characterized the potential neuroprotective effects 
of testosterone on cerebral gray matter in a pilot clinical trial. Ten men with relapsing–remitting MS were 
included in this open-label phase II trial. Subjects were observed without treatment for 6 months, followed 
by testosterone treatment for another 12 months. Focal gray matter loss as a marker for neurodegeneration 
was assessed using voxel-based morphometry. During the non-treatment phase, signiﬁcant voxel-wise gray 
matter decreases were widespread ( p ≤ 0.05 corrected). However, during testosterone treatment, gray matter 
loss was no longer evident. In fact, a signiﬁcant gray matter increase in the right frontal cortex was observed
( p ≤ 0.05 corrected). These observations support the potential of testosterone treatment to stall (and perhaps 
even reverse) neurodegeneration associated with MS. Furthermore, they warrant the investigation of testos- 
terone’s neuroprotective effects in larger, placebo controlled MS trials as well as in other neurodegenerative 
diseases. This is the ﬁrst report of gray matter increase as the result of treatment in MS. 
c © 2014 The Authors. Published by Elsevier Inc. 
This is an open access article under the CC BY-NC-SA license 
( http: // creativecommons.org / licenses / by-nc-sa / 3.0 / ). . Introduction 
Multiple sclerosis (MS) is a putative autoimmune disease char- 
cterized by a relapsing–remitting disease course leading to progres- 
ive disability, inﬂammation, and neurodegeneration ( Vigeveno et al., 
012 ). MS relapses are associated with inﬂammation and the devel- 
pment of white matter lesions. As a result, anti-inﬂammatory treat- 
ents have been developed based on their ability to reduce relapses 
nd white matter lesions. However, inﬂammatory activity and white 
atter lesion burden are only weakly correlated with clinical disease 
rogression ( Brex et al., 2002 ). Gray matter (GM) atrophy correlates 
trongly with clinical disability ( Ontaneda et al., 2012 ; Rudick and 
rapp, 2009 ; Vigeveno et al., 2012 ) and neurodegeneration in MS ( Bo, 
009 ; Gold and Voskuhl, 2009 ; Rudick and Trapp, 2009 ; Vigeveno * Correspondence to: Allan Mackenzie-Graham, Department of Neurology, David 
effen School of Medicine at UCLA, 710 Westwood Plaza 4256 B, Los Angeles, CA 
0095, USA. 
E-mail address: amg@ucla.edu (A. Mackenzie-Graham). 
213-1582/ $ - see front matter c © 2014 The Authors. Published by Elsevier Inc. This is an open
y-nc-sa / 3.0 / ). 
ttp://dx.doi.org/10.1016/j.nicl.2014.03.001 et al., 2012 ). This atrophy is evident from the earliest stages of dis- 
ease, even before a clinically deﬁnite diagnosis can be made ( Dalton 
et al., 2004 ) and continues throughout the disease course ( Fisher et 
al., 2008 ). Consequently, GM atrophy has been suggested as a sur- 
rogate marker for disease progression and neurodegeneration in MS 
( Grassiot et al., 2009 ). GM atrophy has produced different results 
than inﬂammatory markers as outcome measures in clinical trials: 
while anti-inﬂammatory treatments in MS have been shown to re- 
duce the occurrence of inﬂammatory markers such as new white 
matter lesions or relapse rates, their effects on GM atrophy and per- 
manent disability have been modest ( Hardmeier et al., 2005 ; Miller 
et al., 2007 ; Rao et al., 2002 ). To effectively target gray matter atrophy 
and diminish or prevent permanent disability in MS, neuroprotective 
therapies are needed. 
Testosterone has been shown to be neuroprotective in animal 
studies ( Gold and Voskuhl, 2009 ; Hussain et al., 2013 ) including 
the most widely used MS model, experimental autoimmune en- 
cephalomyelitis (EAE) ( Bebo et al., 1999 ; Dalal et al., 1997 ; Ziehn et al., 
2012 ). Analogously, we hypothesized that testosterone treatment in 
human disease may be neuroprotective and this would be reﬂected  access article under the CC BY-NC-SA license ( http: // creativecommons.org / licenses / 



















































































































 as a slowing of gray matter atrophy. Thus, the aim of the current
study was to evaluate the effects of testosterone treatment on local
changes in gray matter volume in MS. Changes in local gray matter
volume were quantiﬁed using voxel-based morphometry (VBM), a
sophisticated, objective whole-brain analysis technique ( Draganski
et al., 2004 ). Ten male patients with MS were enrolled in an open-
label phase II clinical trial. The patients were observed prior to treat-
ment for 6 months (observation phase), followed by a 12-month pe-
riod of treatment with testosterone. To account for “wash-in effects”,
this 12-month treatment period was divided into an initial 6-month
transition phase, which allowed the drug to take action, followed by
a 6-month protection phase. Statistically signiﬁcant changes in GM
concentration were mapped for each phase and the GM volume of
these localized changes was plotted as a percent change. In addition,
the annualized whole-brain GM atrophy rate was calculated in a sup-
plementary analysis. 
2. Material and methods 
2.1. Study design and subjects 
Participants were eligible if they met the criteria for clinically def-
inite relapsing–remitting MS, had had at least one clinical relapse
or the appearance of at least one enhancing lesion on MRI over the
preceding two years, but were not receiving disease-modifying treat-
ment. The original study has been described in detail ( Sicotte et al.,
2007 ). Brieﬂy, this study was an open label phase II trial to assess
the safety and tolerability of testosterone treatment using 10 g of gel
containing 100 mg of testosterone (Androgel) applied topically daily
for one year. The ten men enrolled had a median Expanded Disability
Status Scale (EDSS) score of 2.0 (range: 1.5–2.5), a median disease du-
ration of 12.5 years (range: 0.5–25.0 years), and a mean age of 46 years
(range: 29–61 years). A cross-over trial design was chosen, where sub-
jects served as their own controls. The protocol was approved by the
University of California Los Angeles (UCLA) Human Subjects Protec-
tion Committee and the institutional review board of the Los Angeles
Biomedical Research Institute at Harbor-UCLA Medical Center. 
Contrast-enhanced, FLAIR, and high-resolution T1-weighted brain
MRIs were obtained every month from baseline (month 0) until the
end of the trial (month 18). All ten subjects completed all nineteen
monthly scans (baseline plus monthly scans for 18 months) and were
included in the current analysis. Testosterone treatment started at the
end of month six. To allow the drug enough time to work (“wash-in”),
we divided the trial into three parts: an untreated observation phase,
a transition phase, and a protection phase. The observation phase
was between baseline and end of month six. The transition phase was
deﬁned as end of month six through end of month twelve, leaving the
last six months of the trial as the protection phase. 
2.2. Image acquisition and processing 
Magnetic resonance imaging (MRI) data was acquired on a 1.5 T
Siemens Sonata scanner using a T1-weighted sequence (MPRAGE)
with the following parameters: TR = 1900 ms, TE = 4.38 ms, ﬂip
angle = 15 ◦, 128 sagittal slices, matrix: 256 × 256, and voxel dimen-
sions: 0.9375 × 0.9375 × 1.2 mm 3 . In addition, a Fluid Attenuated
Inversion Recovery (FLAIR) sequence was obtained during the same
session using the following parameters: TR = 9140 ms, TE = 100 ms,
ﬂip angle = 180 ◦, 50 axial slices, matrix: 256 × 256, and voxel di-
mensions: 0.9375 × 0.9375 × 3 mm 3 . Brain images were processed
and examined using SPM8, the LST toolbox, and the VBM8 Toolbox
following previously described methods ( Luders et al., 2009 ; Schmidt
et al., 2012 ). This processing consisted of lesion in-painting to prevent
a possible confound of white matter lesions on tissue segmentation,
followed by tissue-segmentation and normalization to a common ref-
erence space that allows for voxel-wise testing. Brieﬂy, white matterlesions were automatically delineated using a lesion-growing algo-
rithm ( Schmidt et al., 2012 ) that used information from both the FLAIR
and T1-weighted images simultaneously. The lesion growing algo-
rithm was validated and ﬁne-tuned using manual delineations of le-
sions as described ( Schmidt et al., 2012 ). Based on these delineations,
the lesions were in-painted as white matter in the T1-weighted scans
( Chard et al., 2010 ; Schmidt et al., 2012 ) and the in-painted images
were quality controlled to assure accuracy. To accommodate for the
longitudinal design of this study, the lesion in-painted images were
subsequently realigned for each subject using half-way registrations
and corrected for bias-ﬁeld inhomogeneities using the VBM8 Toolbox
(see http: // dbm.neuro.uni-jena.de / vbm8 / VBM8-Manual.pdf ). 
Further preprocessing with this toolbox included tissue-
classiﬁcation into gray matter, white matter, and cerebrospinal ﬂuid
followed by a registration to MNI space using linear and non-linear
transformations ( Luders et al., 2009 ; Luders et al., 2013 ). More speciﬁ-
cally, the tissue segmentation algorithm accounted for partial volume
effects ( Tohka et al., 2004 ), and was based on adaptive maximum a
posteriori estimations ( Rajapakse et al., 1997 ), a spatially adaptive
non-local means denoising ﬁlter ( Manjon et al., 2010 ), as well as a
hidden Markov random ﬁeld model ( Cuadra et al., 2005 ). This tissue
classiﬁcation was independent of tissue probability maps ( Luders et
al., 2009 ; Luders et al., 2013 ), thus acting as an additional safeguard
against a potential inﬂuence of lesions and altered geometry. Using
afﬁne registration and the non-linear DARTEL algorithm ( Ashburner,
2007 ), the individual GM and WM segments in native-space were then
normalized to the DARTEL-Template supplied with the VBM8 Tool-
box (see http: // http: // dbm.neuro.uni-jena.de / vbm). This allowed
for a comparison between time-points and subjects on voxel-level,
yielding an extremely high regional speciﬁcity. A quality check was
performed using tools from the VBM8 Toolbox and individual vi-
sual assessment, which yielded no artifacts or failed segmentation /
normalization of the data. Finally, the gray matter segments were
smoothed with a Gaussian kernel (12 mm full width at half maxi-
mum). These smoothed gray matter segments constituted the input
for the statistical model. For visualization, a mean template from all
subjects was created using normalized whole-brain images. This way,
signiﬁcant results from the statistical analysis were directly superim-
posed on the subjects’ mean anatomy for anatomic localization of
signiﬁcant changes in local gray matter volume. 
2.3. Statistical analyses 
The statistical model included all ten subjects and their smoothed
gray matter segments from four time points: at baseline, after
6 months (i.e. at the end of the observation phase), after 12 months
(i.e. at the end of the transition phase), and after 18 months (i.e. at
the end of the protection phase). This selection allowed us to in-
vestigate the voxel-wise volume changes over the three phases of
the trial. Speciﬁcally, a “subject × condition” model was generated
(with condition being the four time points). In this model the inter-
individual differences between subjects were modeled by the sub-
ject factor, while changes between the time points were modeled
for each subject by the condition factor. To control for false positives,
threshold-free cluster enhancement (TFCE) ( Smith and Nichols, 2009 )
in conjunction with family-wise error correction was used to detect
signiﬁcant clusters at p ≤ 0.05. 
Patterns of signiﬁcant local change (i.e. signiﬁcant gray matter de-
crease and increase) were visualized on a series of maximum intensity
projections illustrating signiﬁcant changes during the observation,
transition, and protection phases. In a subsequent step, the exact lo-
cations of gray matter change during the observation and protection
phases were mapped on the mean template, as described above. The
time course of the volumetric changes for each signiﬁcance cluster
was extracted over all eighteen months of the trial and plotted as
percent change to better assess the effects of testosterone therapy on






























































signiﬁcance ( p ) 
Coordinates in MNI 
space (x, y, z) 
Decrease during observation phase: 
1 239,330 0.0004 −14, −21, 48 
Decrease during transition phase: 
1 2293 0.012 −26, −13, −20 
2 1710 0.016 21, 48, 6 
3 836 0.018 −48, −82, −5 
4 206 0.039 16, 0, 40 
5 174 0.045 −34, 47, −18 
6 26 0.049 −36, −48, 39 
Increase during protection phase: 
1 3719 0.011 33, 6, 61 
p values and coordinates are provided for one representative local maximum within 
the signiﬁcance cluster. 
MNI = Montreal Neurological Institute. ray matter volume. 
.4. Supplemental analyses 
For the supplemental analysis of gray matter changes, lesion in- 
ainted images for each time-point were corrected for bias-ﬁeld in- 
omogeneities using the VBM8 Toolbox. Whole-brain masks were 
enerated using the Brain Surface Extractor and manually corrected 
y a single investigator (AMG) in BrainSuite 13 ( Shattuck and Leahy, 
002 ). Whole-brain masks were applied to the lesion in-painted im- 
ges and segmented into cerebrospinal ﬂuid, gray matter, and white 
atter using the FSL Automated Segmentation Tool (FAST) ( Zhang et 
l., 2001 ), the segmentation tool used in SIENA and SIENAX ( Smith et 
l., 2002 ; Smith et al., 2004 ). Annualized gray matter atrophy rates 
ere calculated for each treatment phase for each patient by calculat- 
ng the best-ﬁt line through the gray matter volume measures during 
he treatment period and multiplying the slope of the line (change in 
ray matter volume / month) by 12 months. Differences in gray mat- 
er atrophy rates between the observation, transition, and protection 
hases were assessed using paired t -tests. 
For the supplemental analysis of white matter changes, lesion 
asks for each time-point were warped to MNI space and their over- 
ap calculated. In addition, lesion volumes in native space were calcu- 
ated for every subject and month (months 0–18) to assess a change 
n lesion volume over time. Differences in overall lesion volume be- 
ween the observation and protection phases were assessed using 
aired t -tests. Finally, the number of gadolinium-enhancing lesions 
as assessed for every subject and month (months 0–18). A non- 
arametric Friedman test was applied to test for differences in the 
umber of enhancing lesions between the observation and protec- 
ion phases ( Supplement 2 ). 
.5. Scan–rescan reliability 
To assess the scan–rescan reliability of our measurements, ten 
atients were scanned within two weeks of each other and had no 
linical change in their disease between scans. We determined that 
he average GM volume difference was 0.22% (1.2 ± 1.8 cm 3 ). 
. Results 
During the observation phase, i.e. when patients received no treat- 
ent, we observed a signiﬁcant voxel-wise GM loss across the entire 
rain ( Fig. 1a , Table 1 ). This loss was widespread throughout cortical, 
ubcortical, and cerebellar structures, extending from its maximum 
n the paracentral lobe along the central sulcus to the inferior frontal 
nd superior parietal regions ( p = 0.0004 at its maximum). The tha- 
amus and basal ganglia also showed highly signiﬁcant effects ( Fig. 
 a). Measurement of GM volume changes within this cluster over 
ime demonstrated a signiﬁcant decrease in the observation phase 
 p = 0.00006), which leveled off completely during the protection 
hase ( Fig. 2b ). 
During the transition phase, substantially less GM loss was ob- 
erved and instead of one large, diffuse cluster, we observed several 
iscrete clusters ( Fig. 1b , Table 1 ). In the protection phase, essentially 
o further atrophy occurred. Instead, a signiﬁcant increase in GM was 
bserved in a cluster within the right frontal cortex ( Fig. 1c ), with a 
aximum located in the right middle frontal gyrus ( p = 0.011) ( Fig. 
c , Table 1 ). The posterior portion of this cluster of signiﬁcant gray 
atter increase included the motor and premotor regions, while the 
aximum of signiﬁcance was located anterior to these regions. Mea- 
urement of GM volume changes within this cluster over time demon- 
trated a signiﬁcant decrease in the observation phase ( p = 0.00034), 
ollowed by a signiﬁcant increase in the protection phase ( p = 0.002) 
 Fig. 2d ). Overall, the cluster’s volume at month 18 was not statisti- 
ally different from the volume at baseline ( p = 0.7048). Whole-brain gray matter changes over the course of the trial were 
consistent with our ﬁndings of decreased localized gray matter at- 
rophy ( Supplement 1 ). The annualized gray matter atrophy rate in 
these untreated MS patients during the observation phase (2.87%) 
was consistent with previous reports of gray matter atrophy rates in 
similar untreated or placebo-treated MS populations, speciﬁcally an- 
nualized gray matter atrophy rates of 0.86%–3.57% in the context of 
0.47%–0.94% annualized percent brain parenchymal volume atrophy 
rates have been reported ( Chard et al., 2004 ; Chen et al., 2004 ; Dalton 
et al., 2004 ; Healy et al., 2009 ; Tiberio et al., 2005 ). This pretreatment 
atrophy was halted in the protection phase (0.18%). 
The number and volume of enhancing lesions in white matter were 
low in the majority of subjects, consistent with the relatively benign 
clinical course of the subjects choosing to not take DMTs in this trial. 
Given the low level of enhancement at baseline in the cohort, it was 
not surprising that a reduction in enhancing lesions was not observed 
with testosterone treatment. In fact, neither the number of enhancing 
lesions nor the volume of FLAIR lesions changed signiﬁcantly over 
time. Further, no temporal or spatial relationship between lesions 
and GM changes was observed ( Supplement 2 ). 
4. Discussion 
The widespread GM loss observed herein by VBM during the ob- 
servation phase is consistent with previous observations ( Grassiot 
et al., 2009 ; Prinster et al., 2006 ; Vigeveno et al., 2012 ). Speciﬁcally, 
regional GM atrophy in MS has previously been shown in frontal cor- 
tical regions ( Bendfeldt et al., 2009 ; Grassiot et al., 2009 ; Prinster 
et al., 2006 ), subcortical structures such as the thalamus ( Ceccarelli 
et al., 2012 ; Grassiot et al., 2009 ; Vigeveno et al., 2012 ) and cau- 
date ( Ceccarelli et al., 2012 ; Grassiot et al., 2009 ; Prinster et al., 
2006 ; Vigeveno et al., 2012 ), as well as in the cerebellum ( Bendfeldt 
et al., 2009 ). However, during testosterone treatment this GM loss 
was stalled diffusely and even reversed in the right frontal cortex, 
suggesting a treatment-related recovery of the volume loss. To our 
knowledge, this is the ﬁrst report of a treatment-induced GM vol- 
ume increase in MS, which stands in stark contrast to previous out- 
comes on gray matter atrophy in anti-inﬂammatory treatment trials 
( Hardmeier et al., 2005 ; Miller et al., 2007 ; Rao et al., 2002 ). This 
observation is particularly interesting since we found no signiﬁcant 
correlations between gray matter loss and changes in white mat- 
ter lesion volume or in newly occurring lesions during testosterone 
treatment. Since lesions are thought to be a marker of inﬂammatory 
activity, this is consistent with testosterone’s effects being neuropro- 
tective rather than anti-inﬂammatory. This observation also supports 
the notion that MS pathogenesis consists of relatively distinct inﬂam- 
matory and neuroprotective components. This in turn may explain 
Florian Kurth et al. / NeuroImage: Clinical 4 (2014) 454–460 457 
Fig. 1. Regional gray matter volume increase in testosterone treated men with MS. (a) Signiﬁcant gray matter changes during the observation phase, (b) the transition phase, 
and (c) the protection phase, threshold at p ≤ 0.05, FWE-corrected for multiple comparisons. Displayed are maximum intensity projections superimposed onto the SPM standard 
glass brain together with a rendering onto the mean template. Decreases are shown in blue, increases in red. Note the signiﬁcant gray matter increase (accompanied by a lack of 
signiﬁcant gray matter decrease ) during the protection phase. 
Fig. 2. Regional volume changes over time. (a) Regional GM decreases during the observation phase. Heat maps visualize regional differences in the level of signiﬁcance, thresholded 
at p ≤ 0.05, FWE-corrected for multiple comparisons. (b) The widespread GM decreases seen during the observation phase (P1) were arrested during testosterone treatment (P2 
and P3). No GM decrease was observed during the protection phase (P3). (c) Regional GM increases during the protection phase. Heat maps visualize regional differences in the 

























 why anti-inﬂammatory treatments prevent relapses and newly oc-
curring lesions, but fail to exhibit a similar impact on long-term dis-
ability and gray matter atrophy ( Hardmeier et al., 2005 ; Miller et al.,
2007 ; Rao et al., 2002 ). 
GM increases have previously been observed in healthy individ-
uals ( Bezzola et al., 2011 ; Boyke et al., 2008 ; Draganski et al., 2004 ;
Draganski et al., 2006 ) and were hypothesized to be caused by in-
creased synaptogenesis and / or neurogenesis ( Draganski et al., 2006 ).
Conversely, neuronal cell death and synaptic loss have been observed
in gray matter lesions in MS by pathology ( Bo, 2009 ), with these
processes posited to underlie gray matter loss ( Rudick and Trapp,
2009 ). Protective signaling pathways and neurotrophic signaling have
also been shown to be activated in the gray matter of MS patients,though they do not appear to be sufﬁcient to forestall gray matter
loss ( Bo, 2009 ). Testosterone treatment may shift the balance be-
tween degenerative and protective processes by acting on these sig-
naling pathways, thus preserving neurons and synapses. Observa-
tions from testosterone treatment in the MS animal model, EAE, sup-
port this interpretation. Speciﬁcally, testosterone treatment resulted
in increased synaptogenesis and preservation of neuronal counts in
the cerebral cortex of mice with EAE ( Ziehn et al., 2012 ). Increased
synaptogenesis in EAE during testosterone treatment was associated
with improved excitatory synaptic function ( Ziehn et al., 2012 ), a well
established electrophysiological biomarker for cognitive function in
mice ( Bach et al., 1995 ; Pompl et al., 1999 ; Seeger et al., 2004 ). 
In view of this association between increased synaptogenesis and































































wmproved cognitive function during testosterone treatment in mice 
ith EAE, it is interesting that cognitive test performance tended to 
mprove in the present cohort, speciﬁcally spatial memory ( p = 0.06) 
nd information processing speed performance ( p = 0.008) ( Sicotte et 
l., 2007 ). Furthermore, the maximum of local gray matter increase 
n the right middle frontal gyrus matched a location that has previ- 
usly been reported to be involved in cognitive tasks. Speciﬁcally, a 
eta-analysis of 275 functional imaging studies demonstrated acti- 
ations in this region during sustained attention, working memory 
nd episodic memory tasks ( Cabeza and Nyberg, 2000 ). Interestingly, 
here were no signiﬁcant changes in other standard MS clinical out- 
omes, namely EDSS score, 9-Hole Peg Test, or the 25 ft timed walk 
 Sicotte et al., 2007 ). 
Since testosterone treatment is known to improve depression, de- 
rease fatigue, and increase muscle mass in healthy men ( Swerdloff 
nd Wang, 2004 ), patients may have also been more active or ex- 
rcised more during testosterone therapy. Indeed, subjects in this 
rial demonstrated a signiﬁcant increase ( p = 0.02) in muscle mass 
ith testosterone treatment ( Sicotte et al. 2007) . Thus, testosterone- 
nduced increased physical activity may have contributed to the 
bserved increase in GM volume, analogous to training studies in 
ealthy individuals ( Bezzola et al., 2011 ; Boyke et al., 2008 ; Draganski 
t al., 2004 ; Draganski et al., 2006 ). Notably, either direct neuropro- 
ection or the beneﬁts of increased physical activity are highly de- 
irable effects and either would represent a favorable therapeutic 
utcome. Although parts of the right primary motor and premotor 
egions were located within the cluster, the maximum of the increase 
as located anteriorly, in an area that is associated with cognitive 
rocessing ( Cabeza and Nyberg, 2000 ). Increased physical activity as 
he sole reason for the observed increase in gray matter may therefore 
eem unlikely, however, no ﬁnal conclusions regarding mechanisms 
an be drawn from the present data. Further studies will therefore 
e needed to distinguish between possible mechanistic contributions 
o the observed increase in regional brain gray matter during testos- 
erone treatment. 
Gray matter increase can be caused by an increase in CNS resident 
ells or substructures (more neurons, dendrites, axons, synapses, glia 
r a combination thereof). Inﬂammation and edema are also possible 
auses that are not speciﬁc to the gray matter, but are nonetheless im- 
ortant to differentiate, particularly in an inﬂammatory disease like 
S. While we cannot differentiate between increases in various CNS 
esident cells / substructures, we can comment on the possibility of 
hether the GM increase was induced by inﬂammation. White matter 
esions and relapses are reliable biomarkers and clinical markers, re- 
pectively, for inﬂammation in MS. No signiﬁcant increases in lesions 
r relapses were observed during the course of the trial ( Sicotte et al. 
007) , which speaks against increases in inﬂammation and edema. 
ndeed, the only changes in clinical outcomes were improvements 
n processing speed and spatial memory. Thus, neurogenesis, synap- 
ogenesis, and increased dendritic arborization are consistent with 
he observed clinical effects and suggest a neuroprotective action of 
estosterone treatment. 
How generalizable our ﬁndings are to all men with MS remains 
nclear. On the one hand, the subjects had refused treatment with 
MTs, which at the time were all given by injection, thereby creating 
 selection bias for men with relatively benign disease, as evidenced 
y the low median EDSS score of 2 at 12 years of disease duration. 
his might suggest that men in this trial may have had relatively 
ower gray matter atrophy rates, with this lower rate potentially more 
menable to testosterone treatment. On the other hand, treatment 
ith DMTs has shown some effect on slowing gray matter atrophy 
ates, so the fact that our subjects were all untreated might suggest 
hat the men in this trial may have had relatively higher gray matter 
trophy rates. Notably, upon assessment of whole gray matter, the 
nnualized atrophy rate of this group was 2.87%, a rate consistent 
ith previously established rates ranging from 0.86% to 3.57% in the MS population. 
In theory, a crossover design may be subject to scanner drift as a 
potential confound, especially if all subjects are enrolled and scanned 
at the same time. In the present study this potential confound was 
minimized by the dispersed enrollment over time, i.e. the last subject 
underwent his baseline scan nearly a year after the ﬁrst. Effectively, 
this means that subjects enrolled later in the trial were still in the ob- 
servation phase (pretreatment control phase), while the earlier sub- 
jects were already in the protection phase (maximum treatment effect 
phase). This makes scanner drift as the driving cause for the observed 
changes unlikely. Furthermore, scanner drift occurs very gradually 
over relatively long periods of time. In our study, only 6 months sep- 
arated the observation phase from the treatment protection phase, 
the two phases with remarkably different levels of GM atrophy. 
The small number of subjects included in this pilot trial restricted 
the analysis to large effects only, leaving smaller effects undetected. 
That is, controlling for type I errors (false positives) leads to an in- 
creased risk of type II errors (false negatives) in a small sample. On 
the one hand, this means that we cannot infer that reaching non- 
signiﬁcance is the same as non-existence, since we rigorously con- 
trolled for type I errors. Therefore, the failure of some GM losses to 
reach statistical signiﬁcance may simply mean that their effects were 
too small to detect with this small sample size. This is equally true for 
GM increases that did not reach statistical signiﬁcance. Accordingly, 
signiﬁcant results with this small sample size are thus indicative of 
large and relevant effects. Since this result of halted GM atrophy and 
the highly novel increase in GM during testosterone therapy has po- 
tentially important implications for MS therapies, this study must be 
replicated and conﬁrmed in a larger trial. Furthermore, the effects of 
testosterone treatment may theoretically be inﬂuenced by age, dis- 
ease duration, and / or disease severity; however, we found no effects 
due to our small sample size. Thus, investigating these possible inter- 
actions in a trial with a larger sample size is needed. 
5. Conclusions 
In summary, these observations may reﬂect the potential of testos- 
terone treatment to reverse gray matter atrophy associated with MS. 
In addition, the present results corroborate the notion that MS is com- 
posed of inﬂammatory and neurodegenerative components, both of 
which will have to be addressed for effective treatment. Since current 
treatments in MS aim primarily to prevent inﬂammation and white 
matter lesions, testosterone may provide a complementary treatment 
aimed at neuroprotection via the preservation / restoration of gray 
matter. As testosterone treatment in this phase II pilot trial raised 
no safety concerns ( Sicotte et al., 2007 ), a larger trial that directly 
assesses such combination treatment is warranted. In addition, sev- 
eral recent reports indicate that testosterone is also being considered 
in other acute and chronic neurodegenerative diseases ( Byers et al., 
2012 ; Carroll and Rosario, 2012 ; Ransome, 2012 ). Our observations in 
MS may therefore encourage and further warrant the study of testos- 
terone in other neurodegenerative diseases. 
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